Jefferies Financial Group’s Apellis Pharmaceuticals APLS Stock Holding History

Jefferies Financial Group’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-23,400	Closed	-$588K	–	1717
2025 Q4	$588K	Hold	23,400	–	–	﹤0.01%	1283
2025 Q3	$530K	Hold	23,400	–	–	﹤0.01%	1065
2025 Q2	$405K	Hold	23,400	–	–	﹤0.01%	951
2025 Q1	$512K	Sell	23,400 -33,600	-59%	-$928K	﹤0.01%	1041
2024 Q4	$1.82M	Hold	57,000	–	–	0.01%	703
2024 Q3	$1.64M	Hold	57,000	–	–	0.01%	649
2024 Q2	$2.19M	Hold	57,000	–	–	0.02%	523
2024 Q1	$3.35M	Buy	57,000 +53,800	+1,681%	+$3.43M	0.03%	421
2023 Q4	$192K	Buy	3,200 +3,100	+3,100%	+$157K	﹤0.01%	1484
2023 Q3	$3.8K	Sell	100 -41,100	-100%	-$1.81M	﹤0.01%	1556
2023 Q2	$3.75M	Buy	41,200 +24,700	+150%	+$2.13M	0.03%	432
2023 Q1	$1.09M	Buy	+16,500	New	+$952K	0.01%	865

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Jefferies Financial Group's APLS Position: Q2 2026 in Review

Jefferies Financial Group sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 219,000 shares — an estimated $8.81M sold.

Jefferies Financial Group first reported a position in APLS in Q1 2023 and held it in 13 quarters. The position peaked at $13.1M in Q1 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Jefferies Financial Group reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Jefferies Financial Group sold 219,000 Apellis Pharmaceuticals shares in Q2 2026, an estimated $8.81M.
Jefferies Financial Group first reported a position in Apellis Pharmaceuticals in Q1 2023 and held it in 13 quarters.
Jefferies Financial Group's Apellis Pharmaceuticals position peaked at $13.1M in Q1 2025.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.